Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas

The authors describe the role of allogeneic hematopoietic stem cell transplantation in cutaneous T-cell lymphomas, and summarize the published data and future perspectives in this area.
[Cancers]
Dumont, M., Peffault de Latour, R., Ram-Wolff, C., Bagot, M., & de Masson, A. (2020). Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas. Cancers, 12(10), 2856. https://doi.org/10.3390/cancers12102856 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Individual HLAs Influence Immunological Events in Allogeneic Stem Cell Transplantation from HLA-Identical Sibling Donors

Scientists retrospectively analyzed 4392 patients with leukemia or myelodysplastic syndrome who received transplants from human leukocyte antigen (HLA)-identical sibling donors to investigate the effects of HLAs on acute graft-versus-host disease.
[Bone Marrow Transplantation]
Morishima, S., Fukuda, T., Doki, N., Mori, T., Onizuka, M., Kawakita, T., Kato, C., Ozawa, Y., Tanaka, M., Kurokawa, M., Kamimura, T., Inoue, M., Tanaka, J., Ichinohe, T., Atsuta, Y., & Morishima, Y. (2020). Individual HLAs influence immunological events in allogeneic stem cell transplantation from HLA-identical sibling donors. Bone Marrow Transplantation, 1–9. https://doi.org/10.1038/s41409-020-01070-3 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Novel Frameshift Autosomal Recessive Loss-of-Function Mutation in SMARCD2 Encoding a Chromatin Remodeling Factor Mediates Granulopoiesis

Scientists report a new patient with a novel frameshift mutation and compared this patient with the previously reported SMARCD2-mutant patients, aiming to provide a more comprehensive understanding of the natural course of the disease.
[Journal of Clinical Immunology]
Yucel, E., Karakus, I. S., Krolo, A., Kiykim, A., Heredia, R. J., Tamay, Z., Cipe, F. E., Karakoc-Aydiner, E., Ozen, A., Karaman, S., Boztug, K., & Baris, S. (2020). Novel Frameshift Autosomal Recessive Loss-of-Function Mutation in SMARCD2 Encoding a Chromatin Remodeling Factor Mediates Granulopoiesis. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-020-00878-4 Cite
Abstract
Bookmark

No account yet? Register

0
Share

UM171-Expanded Cord Blood Transplants Support Robust T Cell Reconstitution with Low Rates of Severe Infections

Scientists assessed T cell reconstitution in patients transplanted with UM171-expanded cord blood (CB) grafts and retrospectively compared it to that of patients receiving unmanipulated CB transplants.
[Biology of Blood and Marrow Transplantation]
Dumont-Lagacé, M., Li, Q., Tanguay, M., Chagraoui, J., Kientega, T., Cardin, G. B., Brasey, A., Trofimov, A., Carli, C., Ahmad, I., Bambace, N. M., Bernard, L., Kiss, T. L., Roy, J., Roy, D.-C., Lemieux, S., Perreault, C., Rodier, F., Dufresne, S. F., … Delisle, J.-S. (2020). UM171-expanded cord blood transplants support robust T cell reconstitution with low rates of severe infections. Biology of Blood and Marrow Transplantation, 0(0). https://doi.org/10.1016/j.bbmt.2020.09.031 Cite
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

0
Share

Therapeutic Angiogenesis Using Autologous Adipose-Derived Regenerative Cells in Patients with Critical Limb Ischaemia in Japan: A Clinical Pilot Study

Adipose tissue was obtained by ordinary liposuction method. Isolated ADRCs were injected into the ischaemic limb. Scientists performed TACT-ADRC procedure in five patients with CLI.
[Scientific Reports]
Therapeutic angiogenesis using autologous adipose-derived regenerative cells in patients with critical limb ischaemia in Japan: a clinical pilot study | Scientific Reports. (n.d.). Retrieved October 5, 2020, from https://www.nature.com/articles/s41598-020-73096-y Cite
Full Article
Bookmark

No account yet? Register

0
Share

Idelalisib Treatment Prior to Allogeneic Stem Cell Transplantation for Patients with Chronic Lymphocytic Leukemia: A Report From the EBMT Chronic Malignancies Working Party

No studies have been reported so far on bridging treatment with idelalisib for patients with chronic lymphocytic leukemia prior to allogeneic hematopoietic cell transplantation. To study potential carry-over effects of idelalisib and to assess the impact of pathway-inhibitor failure researchers performed a retrospective EBMT registry-based study.
[Bone Marrow Transplantation]
Schetelig, J., Chevallier, P., van Gelder, M., Hoek, J., Hermine, O., Chakraverty, R., Browne, P., Milpied, N., Malagola, M., Socié, G., Delgado, J., Deconinck, E., Damaj, G., Maury, S., Beelen, D., Quoc, S. N., Shankara, P., Brecht, A., Mayer, J., … Dreger, P. (2020). Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party. Bone Marrow Transplantation, 1–9. https://doi.org/10.1038/s41409-020-01069-w Cite
Abstract
Bookmark

No account yet? Register

0
Share

A Latent Lineage Potential in Resident Neural Stem Cells Enables Spinal Cord Repair

Researchers uncovered a latent potential in neural stem cells to replace large numbers of lost oligodendrocytes in the injured mouse spinal cord.
[Science]
Llorens-Bobadilla, E., Chell, J. M., Merre, P. L., Wu, Y., Zamboni, M., Bergenstråhle, J., Stenudd, M., Sopova, E., Lundeberg, J., Shupliakov, O., Carlén, M., & Frisén, J. (2020). A latent lineage potential in resident neural stem cells enables spinal cord repair. Science, 370(6512). https://doi.org/10.1126/science.abb8795 Cite
AbstractPress ReleaseGraphical Abstract
Bookmark

No account yet? Register

0
Share

Outcomes of Second Hematopoietic Stem Cell Transplantation Using Reduced‐Intensity Conditioning in an Outpatient Setting

Outpatient second hematoprogenitors transplant after reduced‐intensity conditioning at a single academic center was analyzed. Twenty‐seven consecutive adults who received an allogeneic hematopoietic stem cell transplantation (allo‐HSCT) after an initial auto‐ or allo‐HSCT from 2006 to 2019 were included.
[Hematological Oncology]
Jaime‐Pérez, J. C., Picón‐Galindo, E., Herrera‐Garza, J. L., & Gómez‐Almaguer, D. (n.d.). Outcomes of second hematopoietic stem cell transplantation using reduced-intensity conditioning in an outpatient setting. Hematological Oncology, n/a(n/a). https://doi.org/10.1002/hon.2812 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Reduced Dose of Posttransplant Cyclophosphamide in HLA-Haploidentical Peripheral Blood Stem Cell Transplantation

Scientists conducted two consecutive prospective multicenter phase II studies to evaluate the safety and efficacy of 80 mg/kg of PTCy in 137 patients who underwent HLA-haploidentical peripheral blood stem cell transplantation following reduced-intensity conditioning
[Bone Marrow Transplantation]
Sugita, J., Kamimura, T., Ishikawa, T., Ota, S., Eto, T., Kuroha, T., Miyazaki, Y., Kumagai, H., Matsuo, K., Akashi, K., Taniguchi, S., Harada, M., & Teshima, T. (2020). Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplantation, 1–9. https://doi.org/10.1038/s41409-020-01065-0 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Clinical Effects of Intrathecal Administration of Expanded Wharton Jelly Mesenchymal Stromal Cells in Patients with Chronic Complete Spinal Cord Injury: A Randomized Controlled Study

Patients were randomly assigned to receive a single dose of intrathecal ex vivo-expanded Wharton’s jelly-MSCs from human umbilical cord or placebo and were then switched to the other arm at six months.
[Cytotherapy]
Albu, S., Kumru, H., Coll, R., Vives, J., Vallés, M., Benito-Penalva, J., Rodríguez, L., Codinach, M., Hernández, J., Navarro, X., & Vidal, J. (2020). Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study. Cytotherapy, 0(0). https://doi.org/10.1016/j.jcyt.2020.08.008 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Hematopoietic Stem Cell Transplantation in Children and Adolescents with Nonremission Acute lymphoblastic leukemia

This retrospective analysis aimed to investigate the outcomes associated with hematopoietic stem cell transplantation (HSCT), and the risks of HSCT in children and adolescents with nonremission acute lymphoblastic leukemia.
[Pediatric Blood & Cancer]
Okamoto, Y., Nakazawa, Y., Inoue, M., Watanabe, K., Goto, H., Yoshida, N., Noguchi, M., Kikuta, A., Kato, K., Hashii, Y., Atsuta, Y., & Kato, M. (n.d.). Hematopoietic stem cell transplantation in children and adolescents with nonremission acute lymphoblastic leukemia. Pediatric Blood & Cancer, n/a(n/a), e28732. https://doi.org/10.1002/pbc.28732 Cite
Abstract
Bookmark

No account yet? Register

0
Share
Share